Apexigen, Inc. Common Stock
APGN
APGN was delisted on the 22nd of August, 2023.
17 hedge funds and large institutions have $1.37M invested in Apexigen, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 4 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less funds holding
Funds holding: 20 → 17 (-3)
17% less capital invested
Capital invested by funds: $1.64M → $1.37M (-$273K)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$13.9K |
| 2 |
JC
JBF Capital
Aspen,
Colorado
|
+$4.32K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$1.08K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$165 |
| 5 |
Wells Fargo
San Francisco,
California
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$75K |
| 2 |
Millennium Management
New York
|
-$11K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.77K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$6.57K |
| 5 |
Two Sigma Investments
New York
|
-$5.66K |
APGN Hedge Fund Activity: Q2 2023 in Review
17 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Apexigen, Inc. Common Stock (APGN) for Q2 2023, worth a combined $1.37M — down 17% from $1.64M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of APGN and 1 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $13.9K. The largest seller was CVI Holdings, exiting entirely with an estimated $75K sold.
- 17 institutional investors held Apexigen, Inc. Common Stock (APGN) as of Q2 2023, down from 20 in Q1 2023.
- Funds reported $1.37M of Apexigen, Inc. Common Stock stock for Q2 2023, down 17% quarter-over-quarter.
- 1 fund opened new Apexigen, Inc. Common Stock positions in Q2 2023 and 4 closed out, a net change of -3 holders.
- The largest Apexigen, Inc. Common Stock buyer in Q2 2023 was Renaissance Technologies, an estimated $13.9K added.
- The largest Apexigen, Inc. Common Stock seller in Q2 2023 was CVI Holdings, an estimated $75K sold.
Based on aggregated 13F filings for Q2 2023.